IDEXX Laboratories, Inc. $IDXX Shares Purchased by MUFG Securities EMEA plc

MUFG Securities EMEA plc increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 113.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,274 shares of the company’s stock after acquiring an additional 1,743 shares during the period. MUFG Securities EMEA plc’s holdings in IDEXX Laboratories were worth $2,215,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Beacon Investment Advisory Services Inc. boosted its position in shares of IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the period. Nordea Investment Management AB boosted its position in shares of IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after purchasing an additional 8,845 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $1,966,000. Diversified Trust Co. boosted its position in shares of IDEXX Laboratories by 223.5% in the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after purchasing an additional 2,901 shares during the period. Finally, NEOS Investment Management LLC boosted its position in shares of IDEXX Laboratories by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock valued at $19,199,000 after purchasing an additional 13,599 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.6%

Shares of IDEXX Laboratories stock opened at $566.79 on Tuesday. The firm has a market cap of $44.71 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 3.27 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The stock has a 50-day simple moving average of $564.32 and a 200-day simple moving average of $635.65.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business earned $2.91 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IDXX shares. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Barclays decreased their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.